Global Information
회사소개 | 문의

세계의 에피제네틱스 시장 분석과 예측 : 기술별, 용도별(종양, 비암질환), 제품별(시약, 장비, 효소, 키트, 서비스), 지역별(2018-2025년)

Epigenetics Market Size, Share & Trends Analysis Report By Technology, By Application (Oncology, Non-oncology), By Product (Reagents, Instruments, Enzyme, Kits, Services), And Segment Forecasts, 2018 - 2025

리서치사 Grand View Research, Inc.
발행일 2018년 09월 상품 코드 731167
페이지 정보 영문 153 Pages
가격
US $ 5,950 ₩ 6,785,300 Unprintable PDF by E-mail (Single User License)
US $ 7,950 ₩ 9,066,100 PDF by E-mail (5-User License) help
DRM(디지털 저작권 관리 시스템)이 장착된 PDF 파일로 2명에서 5명까지 이용할 수 있는 라이선스입니다. 편집 및 인쇄는 가능하며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 9,950 ₩ 11,346,900 PDF by E-mail (Enterprise License) help
동일기업 내 모든 분들이 이용할 수 있는 라이선스입니다. 편집 및 인쇄는 가능하며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.

주의 : 본 보고서는 DRM(디지털 저작권 관리 시스템)이 장착된 PDF 파일로, 라이선스에 따라 자료 이용 및 인쇄 등에 제약이 있을 수 있습니다. 자세한 내용은 라이선스 설명문( )을 참고하여 주시기 바랍니다.



세계의 에피제네틱스 시장 분석과 예측 : 기술별, 용도별(종양, 비암질환), 제품별(시약, 장비, 효소, 키트, 서비스), 지역별(2018-2025년) Epigenetics Market Size, Share & Trends Analysis Report By Technology, By Application (Oncology, Non-oncology), By Product (Reagents, Instruments, Enzyme, Kits, Services), And Segment Forecasts, 2018 - 2025
발행일 : 2018년 09월 페이지 정보 : 영문 153 Pages

세계의 에피제네틱스 시장은 2018-2025년간 19.7%의 연평균 성장률(CAGR)로 추정되며 2025년까지 220억 5,000만 달러 규모 시장으로 성장할 전망입니다. 암 등 에피제네틱스 관련 질환의 세계적인 증가에 의해 시장 성장이 촉진되고 있습니다.

세계의 에피제네틱스(Epigenetics) 시장을 조사했으며, 시장 개요, 용도·기술·제품·지역별 시장 규모 추정과 예측, 시장 동향, 시장 성장 촉진요인 및 저해요인 분석, 시장 기회, 경쟁 상황, 주요 기업 개요 등의 정보를 제공합니다.

목차

제1장 조사 방법

  • 정보 조달
  • 정보 분석
  • 시장 구성과 검증

제2장 주요 요약

  • 시장 현황

제3장 시장 변수, 동향, 범위

제4장 에피제네틱스 시장 : 변수, 동향, 범위

  • 시장 세분화
  • 시장 규모와 성장 전망
  • 시장 기회
  • SWOT 분석
  • Porter's Five Forces 분석
  • 에피제네틱스 - 파이프라인 개요

제5장 에피제네틱스 시장 분석과 예측 : 제품별

  • 시장 동향 분석 : 제품별
  • 시약
  • 키트
    • ChIP 시퀀싱(ChIP-Seq) 키트
    • 전게놈 증폭 키트
    • 중아황산염 변환 키트
    • RNA 시퀀싱 키트
  • 장비
  • 효소
  • 서비스

제6장 에피제네틱스 시장 분석과 예측 : 기술별

  • 시장 동향 분석 : 기술별
  • DNA 메틸화
  • 히스톤 메틸화
  • 히스톤 아세틸화
  • lncRNA(long non-coding RNA)
  • 마이크로 RNA 개변
  • 크로마틴 구조

제7장 에피제네틱스 시장 분석과 예측 : 용도별

  • 시장 동향 분석 : 용도별
  • 종양
    • 고형 종양
    • 액성 종양
  • 비암질환
    • 염증성 질환
    • 대사성 질환
    • 감염증
    • 심혈관 질환
    • 기타

제8장 에피제네틱스 시장 분석과 예측 : 지역별

  • 시장 동향 분석 : 용도별
  • 북미
  • 유럽
  • 아시아태평양
  • 라틴아메리카
  • 중동 및 아프리카

제9장 경쟁 상황

  • 전략 체계
  • Illumina, Inc.
  • Merck Sharp & Dohme Corp
  • Qiagen
  • F. Hoffmann-La Roche Ltd.
  • Eisai Co., Ltd.
  • Novartis AG
  • Abcam plc
  • Diagenode Diagnostics
  • Thermo Fisher Scientific, Inc.
  • Active Motif
  • Zymo Research Corporation
  • CellCentric
  • Chroma Therapeutics Ltd.
  • Oncolys BioPharma Inc.
  • Syndax
  • Valirx
  • Sigma-Aldrich Corporation(Merck KGaA)
KSM 18.11.12

List of Tables

  • TABLE 1 Global cancer cases, 2016
  • TABLE 2 Some major collaboration in epigenetic market
  • TABLE 3 List of key organizations funding epigenetics related R&D worldwide
  • TABLE 4 Pipeline and new product development analysis

List of Figures

  • FIG. 1 Market research process
  • FIG. 2 Information procurement
  • FIG. 3 Primary research pattern
  • FIG. 4 Market research approaches
  • FIG. 5 Value chain based sizing & forecasting
  • FIG. 6 QFD modelling for market share assessment
  • FIG. 7 Market summary
  • FIG. 8 Market trends & outlook
  • FIG. 9 Market segmentation & scope
  • FIG. 10 Global epigenetics market, 2014 - 2025 (USD Million)
  • FIG. 11 Market driver relevance analysis (Current & future impact)
  • FIG. 12 Global population by age group, 2000 - 2050 (in billion)
  • FIG. 13 Population of age 60 years and above, by region (2015 & 2020)
  • FIG. 14 Market restraint relevance analysis (Current & future impact)
  • FIG. 15 Epigenetics key opportunities prioritized
  • FIG. 16 SWOT Analysis, By Factor (political & legal, economic and technological)
  • FIG. 17 Porter's Five Forces Analysis
  • FIG. 18 Epigenetics market product outlook key takeaways
  • FIG. 19 Epigenetics market: Product movement analysis
  • FIG. 20 Epigenetics-based reagents, 2014 - 2025 (USD Million)
  • FIG. 21 Epigenetics-based kits, 2014 - 2025 (USD Million)
  • FIG. 22 ChIP sequencing kit Market, 2014 - 2025 (USD Million)
  • FIG. 23 Whole-genomic amplification kit Market, 2014 - 2025 (USD Million)
  • FIG. 24 Bisulfite conversion kit Market, 2014 - 2025 (USD Million)
  • FIG. 25 RNA sequencing Kit Market, 2014 - 2025 (USD Million)
  • FIG. 26 Others kit Market, 2014 - 2025 (USD Million)
  • FIG. 27 Epigenetics-based instruments Market, 2014 - 2025 (USD Million)
  • FIG. 28 Epigenetics-based enzymes Market, 2014 - 2025 (USD Million)
  • FIG. 29 Epigenetics-based services market, 2014 - 2025 (USD Million)
  • FIG. 30 Epigenetics market technology outlook key takeaways
  • FIG. 31 Epigenetics market: Technology movement analysis
  • FIG. 32 Epigenetics-based DNA methylation market, 2014 - 2025 (USD Million)
  • FIG. 33 Epigenetics-based histone methylation market, 2014 - 2025 (USD Million)
  • FIG. 34 Epigenetics-based histone acetylation market, 2014 - 2025 (USD Million)
  • FIG. 35 Epigenetics-based long non-coding RNA market, 2014 - 2025 (USD Million)
  • FIG. 36 Epigenetics-based microRNA modification market, 2014 - 2025 (USD Million)
  • FIG. 37 Epigenetics-based Chromatin structures market, 2014 - 2025 (USD Million)
  • FIG. 38 Epigenetics market application outlook key takeaways
  • FIG. 39 Epigenetics market: Application movement analysis
  • FIG. 40 Oncology market, 2014 - 2025 (USD Million)
  • FIG. 41 Solid tumors market, 2014 - 2025 (USD Million)
  • FIG. 42 Liquid tumors market, 2014 - 2025 (USD Million)
  • FIG. 43 Non-oncology disorders market, 2014 - 2025 (USD Million)
  • FIG. 44 Inflammatory diseases market, 2014 - 2025 (USD Million)
  • FIG. 45 Metabolic diseases market, 2014 - 2025 (USD Million)
  • FIG. 46 Infectious diseases market, 2014 - 2025 (USD Million)
  • FIG. 47 Cardiovascular diseases market, 2014 - 2025 (USD Million)
  • FIG. 48 Others market, 2014 - 2025 (USD Million)
  • FIG. 49 Regional market place: Key takeaways
  • FIG. 50 Epigenetics market: Regional movement analysis
  • FIG. 51 North America epigenetics market, 2014 - 2025 (USD Million)
  • FIG. 52 U.S. epigenetics market, 2014 - 2025 (USD Million)
  • FIG. 53 Canada epigenetics market, 2014 - 2025 (USD Million)
  • FIG. 54 Europe epigenetics market, 2014 - 2025 (USD Million)
  • FIG. 55 Germany epigenetics market, 2014 - 2025 (USD Million)
  • FIG. 56 U.K. epigenetics market, 2014 - 2025 (USD Million)
  • FIG. 57 Asia Pacific epigenetics market, 2014 - 2025 (USD Million)
  • FIG. 58 Japan epigenetics market, 2014 - 2025 (USD Million)
  • FIG. 59 China epigenetics market, 2014 - 2025 (USD Million)
  • FIG. 60 India epigenetics market, 2014 - 2025 (USD Million)
  • FIG. 61 Latin America epigenetics market, 2014 - 2025 (USD Million)
  • FIG. 62 Brazil epigenetics market, 2014 - 2025 (USD Million)
  • FIG. 63 Mexico epigenetics market, 2014 - 2025 (USD Million)
  • FIG. 64 MEA epigenetics market, 2014 - 2025 (USD Million)
  • FIG. 65 South Africa epigenetics market, 2014 - 2025 (USD Million)
  • FIG. 66 Strategy framework

The global epigenetics market size is expected to reach USD 22.05 billion by 2025, according to a new study by Grand View Research, Inc., progressing at a CAGR of 19.7% during the forecast period. Growing prevalence of cancer and other diseases worldwide with epigenetic modification base is expected to drive the market during the forecast period.

Diagnostic companies are coming up with new products such as antibodies specific for detection of modifications and new upgraded kits for easy and efficient detection of biomarkers. This is estimated to attract pharmaceutical companies to collaborate for development of therapeutic drugs, which will work in favor of the market.

Presence of pipeline drugs and their expected commercialization is anticipated to boost the growth of the market. For instance, Ramucirumab (Cyramza) by Eli Lilly and Company was approved by FDA for use in combination with Folfiri for treatment of patients with metastatic colorectal cancer.

Technology advancements in the epigenetics industry are majorly focusing on detection of methylation markers related to cancer development. For instance, Epi proLung BL Reflex Assay by Epigenomics helps in diagnosis of lung cancer by determining methylation of SHOX2 biomarker gene.

Further key findings from the study suggest:

  • On the basis of product, reagents held the largest share in the market in 2017. They are projected to amount to approximately USD 7.06 billion by 2025 owing to increasing R&D activities in the field of epigenetics
  • The kits segment is expected to post a CAGR of over 20.0% due to need for rapid and accurate detection techniques
  • DNA methylation, on the basis of technology, held the leading revenue share in the market in 2017, accounting for just over 47.0%. Rapid adoption of advanced techniques such as methylation sensitive PCR (MSP) to improve diagnostics efficiency is poised to bolster the growth of the segment
  • North America commanded the leading position in the global arena with a share of 40.0% in 2017. The growth of the regional market can be attributed to increasing prevalence of cancer and growing collaborations between large pharmaceutical firms for development of improved therapeutics
  • Asia Pacific is estimated to register a noteworthy CAGR of 22.1% during the forecast period owing to presence of large target population coupled with high unmet clinical needs

Some of the major players of epigenetics market are: Illumina; Abcam; Diagenode; Thermo Fisher Scientific; Merck; Zymo research; Qiagen; CellCentric Ltd; Chroma Therapeutics Ltd; Eisai Co. Ltd; Novartis International AG; Oncolys Biopharma Inc.; Syndax Pharmaceuticals, Inc.; Valirx Plc; and Sigma-Aldrich Corporation.

Extensive R&D initiatives for development of novel drugs and presence of strong product pipeline are expected to further boost market growth over the forecast period.

Table of Contents

Chapter 1: Research Methodology

  • 1.1 Information Procurement
  • 1.2 Information or Data Analysis
  • 1.3 Market Formulation & Validation

Chapter 2: Executive Summary

  • 2.1 Market Snapshot

Chapter 3: Market Variables, Trends & Scope

Chapter 4: Epigenetics Market Variables, Trends & Scope

  • 4.1 Market Segmentation
  • 4.2 Market Size and Growth Prospects
    • 4.2.1 Market driver analysis
      • 4.2.1.1 Increasing prevalence of target diseases
      • 4.2.1.2 Growing global geriatric population
      • 4.2.1.3 Increasing collaborations between biotechnology companies, pharmaceutical companies, and academic research institutes
      • 4.2.1.4 Presence of funding programs to promote and support research & development
      • 4.2.1.5 Technological advancements
    • 4.2.2 Market restraint analysis
      • 4.2.2.1 Inefficiency in identification and validation of biomarkers
      • 4.2.2.2 Presence of complex regulatory framework
  • 4.3 Key Opportunities Prioritized
  • 4.4 Epigenetics - SWOT Analysis, by Factor (Political & legal, economic and technological)
  • 4.5 Industry Analysis - Porter's
  • 4.6 Epigenetics-Pipeline overview

Chapter 5: Epigenetics Market Product Estimates & Trend Analysis

  • 5.1 Epigenetics Market: Product Movement Analysis
  • 5.2 Epigenetics-based reagents
    • 5.2.1 Epigenetics-based reagents, 2014 - 2025 (USD Million)
  • 5.3 Epigenetics-based kits
    • 5.3.1 Epigenetics-based kits, 2014 - 2025 (USD Million)
    • 5.3.2 ChIP sequencing kit
      • 5.3.2.1 ChIP sequencing kit Market, 2014 - 2025 (USD Million)
    • 5.3.3 Whole-genomic amplification kit
      • 5.3.3.1 Whole-genomic amplification kit Market, 2014 - 2025 (USD Million)
    • 5.3.4 Bisulfite conversion kit
      • 5.3.4.1 Bisulfite conversion kit Market, 2014 - 2025 (USD Million)
    • 5.3.5 RNA sequencing Kit
      • 5.3.5.1 RNA sequencing Kit Market, 2014 - 2025 (USD Million)
      • 5.3.5.2 Others
    • 5.3.6 Others kit Market, 2014 - 2025 (USD Million)
  • 5.4 Epigenetics-based instruments Market
    • 5.4.1 Epigenetics-based instruments Market, 2014 - 2025 (USD Million)
  • 5.5 Epigenetics-based enzymes Market
    • 5.5.1 Epigenetics-based enzymes Market, 2014 - 2025 (USD Million)
  • 5.6 Epigenetics-based services market
    • 5.6.1 Epigenetics-based services Market, 2014 - 2025 (USD Million)

Chapter 6: Epigenetics Market Technology Estimates & Trend Analysis

  • 6.1 Epigenetics Market: Technology Movement Analysis
  • 6.2 Epigenetics-based DNA methylation market
    • 6.2.1 Epigenetics-based DNA methylation market, 2014 - 2025 (USD Million)
  • 6.3 Epigenetics-based histone methylation market
    • 6.3.1 Epigenetics-based histone methylation market, 2014 - 2025 (USD Million)
  • 6.4 Epigenetics-based histone acetylation market
    • 6.4.1 Epigenetics-based histone acetylation market, 2014 - 2025 (USD Million)
  • 6.5 Epigenetics-based long non-coding RNA market
    • 6.5.1 Epigenetics-based long non-coding RNA market, 2014 - 2025 (USD Million)
  • 6.6 Epigenetics-based microRNA modification market
    • 6.6.1 Epigenetics-based microRNA modification market, 2014 - 2025 (USD Million)
  • 6.7 Epigenetics-based Chromatin structures market
    • 6.7.1 Epigenetics-based Chromatin structures market, 2014 - 2025 (USD Million)

Chapter 7: Epigenetics Market Application Estimates & Trend Analysis

  • 7.1 Epigenetics Market: Application Movement Analysis
  • 7.2 Oncology
    • 7.2.1 Oncology market, 2014 - 2025 (USD Million)
    • 7.2.2 Solid tumors
    • 7.2.3 Solid tumors market, 2014 - 2025 (USD Million)
    • 7.2.4 Liquid tumors
    • 7.2.5 Liquid tumors market, 2014 - 2025 (USD Million)
  • 7.3 Non-oncology disorders
    • 7.3.1 Non-oncology disorders market, 2014 - 2025 (USD Million)
    • 7.3.2 Inflammatory diseases
    • 7.3.3 Inflammatory diseases market, 2014 - 2025 (USD Million)
    • 7.3.4 Metabolic diseases
    • 7.3.5 Metabolic diseases market, 2014 - 2025 (USD Million)
    • 7.3.6 Infectious diseases
    • 7.3.7 Infectious diseases market, 2014 - 2025 (USD Million)
    • 7.3.8 Cardiovascular diseases
    • 7.3.9 Cardiovascular diseases market, 2014 - 2025 (USD Million)
    • 7.3.10 Others
    • 7.3.11 Others market, 2014 - 2025 (USD Million)

Chapter 8: Regional Estimates & Trend Analysis, by Product

  • 8.1 Epigenetics market share by region, 2017 & 2025
  • 8.2 North America
    • 8.2.1 North America epigenetics market, 2014 - 2025 (USD Million)
    • 8.2.2 U.S.
      • 8.2.2.1 U.S. epigenetics market, 2014 - 2025 (USD Million)
    • 8.2.3 Canada
      • 8.2.3.1 Canada epigenetics market, 2014 - 2025 (USD Million)
  • 8.3 Europe
    • 8.3.1 Europe epigenetics market, 2014 - 2025 (USD Million)
    • 8.3.2 Germany
      • 8.3.2.1 Germany epigenetics market, 2014 - 2025 (USD Million)
    • 8.3.3 U.K.
      • 8.3.3.1 U.K. epigenetics market, 2014 - 2025 (USD Million)
  • 8.4 Asia Pacific
    • 8.4.1 Asia Pacific epigenetics market, 2014 - 2025 (USD Million)
    • 8.4.2 Japan
      • 8.4.2.1 Japan epigenetics market, 2014 - 2025 (USD Million)
    • 8.4.3 China
      • 8.4.3.1 China epigenetics market, 2014 - 2025 (USD Million)
    • 8.4.4 India
      • 8.4.4.1 India epigenetics market, 2014 - 2025 (USD Million)
  • 8.5 Latin America
    • 8.5.1 Latin America epigenetics market, 2014 - 2025 (USD Million)
    • 8.5.2 Brazil
      • 8.5.2.1 Brazil epigenetics market, 2014 - 2025 (USD Million)
    • 8.5.3 Mexico
      • 8.5.3.1 Mexico epigenetics market, 2014 - 2025 (USD Million)
  • 8.6 MEA
    • 8.6.1 MEA epigenetics market, 2014 - 2025 (USD Million)
    • 8.6.2 South Africa
      • 8.6.2.1 South Africa epigenetics market, 2014 - 2025 (USD Million)

Chapter 9: Competitive Landscape

  • 9.1 Strategy Framework
  • 9.2 Illumina, Inc.
    • 9.2.1 Company overview
    • 9.2.2 Financial performance
    • 9.2.3 Product benchmarking
    • 9.2.4 Strategic initiatives
  • 9.3 Merck Sharp & Dohme Corp
    • 9.3.1 Company overview
    • 9.3.2 Financial performance
    • 9.3.3 Product benchmarking
    • 9.3.4 Strategic initiatives
  • 9.4 Qiagen
    • 9.4.1 Company overview
    • 9.4.2 Financial performance
    • 9.4.3 Product benchmarking
    • 9.4.4 Strategic initiatives
  • 9.5 F. Hoffmann-La Roche Ltd.
    • 9.5.1 Company overview
    • 9.5.2 Financial performance
    • 9.5.3 Product benchmarking
    • 9.5.4 Strategic initiatives
  • 9.6 Eisai Co., Ltd.
    • 9.6.1 Company overview
    • 9.6.2 Financial performance
    • 9.6.3 Product benchmarking
    • 9.6.4 Strategic initiatives
  • 9.7 Novartis AG
    • 9.7.1 Company overview
    • 9.7.2 Financial performance
    • 9.7.3 Product benchmarking
    • 9.7.4 Strategic initiatives
  • 9.8 Abcam plc
    • 9.8.1 Company overview
    • 9.8.2 Financial performance
    • 9.8.3 Product benchmarking
    • 9.8.4 Strategic initiatives
  • 9.9 Diagenode Diagnostics
    • 9.9.1 Company overview
    • 9.9.2 Financial performance
    • 9.9.3 Product benchmarking
    • 9.9.4 Strategic initiatives
  • 9.10 Thermo Fisher Scientific, Inc.
    • 9.10.1 Company overview
    • 9.10.2 Financial performance
    • 9.10.3 Product benchmarking
    • 9.10.4 Strategic initiatives
  • 9.11 Active Motif
    • 9.11.1 Company overview
    • 9.11.2 Financial performance
    • 9.11.3 Product benchmarking
    • 9.11.4 Strategic initiatives
  • 9.12 Zymo Research Corporation
    • 9.12.1 Company overview
    • 9.12.2 Financial performance
    • 9.12.3 Product benchmarking
    • 9.12.4 Strategic initiatives
  • 9.13 CellCentric
    • 9.13.1 Company overview
    • 9.13.2 Product benchmarking
    • 9.13.3 Strategic initiatives
  • 9.14 Chroma Therapeutics Ltd.
    • 9.14.1 Company overview
    • 9.14.2 Financial performance
    • 9.14.3 Product benchmarking
    • 9.14.4 Strategic initiatives
  • 9.15 Oncolys BioPharma Inc.
    • 9.15.1 Company overview
    • 9.15.2 Financial performance
    • 9.15.3 Product benchmarking
    • 9.15.4 Strategic initiatives
  • 9.16 Syndax
    • 9.16.1 Company overview
    • 9.16.2 Financial performance
    • 9.16.3 Product benchmarking
    • 9.16.4 Strategic initiatives
  • 9.17 Valirx
    • 9.17.1 Company overview
    • 9.17.2 Financial performance
    • 9.17.3 Product benchmarking
    • 9.17.4 Strategic initiatives
  • 9.18 Sigma-Aldrich Corporation (Merck KGaA)
    • 9.18.1 Company overview
    • 9.18.2 Financial performance
    • 9.18.3 Product benchmarking
    • 9.18.4 Strategic initiatives
Back to Top
전화 문의
이용안내
 
BCC Research